Carl Icahn has not been tweeting much and when he does it has been vague but this morning the billionaire possible future treasury of the United States Secretary was back on the micro blogging platform to make a big announcement. Icahn tweeted a link to a statement about a big acquisition of Allergan. He notes that he was close with the CEO of Forest Labs which was recently acquired by Allergan. In the statement, Icahn expresses support for the current CEO of AGN but does not say much more – we look forward to what Icahn has in store for the company. Meanwhile, shares of AGN are up 1.7 percent in early trading on the Icahn news.
See the full statement below.
Statement Regarding Allergan by Carl Icahn
We have recently acquired a large position in Allergan and are very supportive of CEO Brent Saunders. We were instrumental in bringing Brent on board as the new CEO of Forest Labs a few years ago and worked cooperatively and constructively with him to help increase value for all Forest shareholders. Less than a year later Forest was acquired by Actavis (which subsequently merged with Allergan) resulting in massive gains for Forest shareholders. While we at that time disposed of our position in Forest, we still have always maintained great respect for Brent. We have every confidence in Brent’s ability to enhance value for all Allergan shareholders.
Important Disclosure Information
We do not recommend or advise, nor do we intend to recommend or advise, any person to purchase or sell securities and no one should rely on this statement to purchase or sell securities or consider purchasing or selling securities. This statement does not purport to be, nor should it be read, as an expression of any opinion or prediction as to the price at which Allergan’s securities may trade at any time. Our views on Allergan and our holdings of Allergan securities could change at any time. We may sell any or all of our holdings or increase our holdings by purchasing additional securities. We may take any of these or other actions regarding Allergan without updating this statement or providing any notice whatsoever of any such changes. Investors should make their own decisions regarding Allergan and its prospects without relying on, or even considering, any of the information contained in this statement.
